Best Oncology Companies in India
The 102 best Oncology companies in India in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Bugworks Research.
India's Oncology sector is earning real money. This directory ranks the best oncology companies in India by disclosed equity funding and recent funding momentum, tracking 102 ventures with $319M in total disclosed capital and, critically, $95M in combined revenue across 39 filers.
Median revenue sits at $173,908, but that number undersells the spread. Beta Drugs filed $42M in revenue, up 23% year-over-year, and nets $5M profit, which is 245 times the sector's median net income. Immunoadoptive Cell Therapy posted $7M in revenue with a staggering 512% growth rate. Adley Formulations pulled $15M at 47% growth. The median growth rate across filers is 14%, and you can see why I'd call that a floor, not a ceiling. The global oncology market sits at roughly $250.9B in 2025, forecast to reach $668.3B by 2034 at an 11.5% CAGR, driven by precision medicine and rising cancer incidence. India's piece of that is moving fast, as India's oncology market shifts toward precision medicine and ADC therapies signals. Cost-containment policies add pressure, but the revenue filings here show the sector is absorbing it.
- Oncology R&D: emerging therapies and new challenges
- Oncology Market Size to Surpass USD 903.81 Billion by 2034
Our analysis of 50 Oncology companies
$16.3b in tracked funding; 86% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Oncology companies in India
| # | Company | Revenue | Disclosed funding | Last round | Employees | Founder | Web popularity | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Beta Drugs Developer of therapeutics for oncology and dermatology 69Product top 14%Moat top 18%Fin. health top 26%Market top 29% All 11 signals ▾Producttop 14% Moattop 18% Fin. healthtop 26% Markettop 29% Innovationtop 34% Growthtop 40% Fundingtop 42% Talentbottom 49% Techbottom 39% Globalbottom 32% Newsbottom 21% Product: 7 distinct product lines · Company stage: Public Moat: Top 1% by revenue among 34 tracked Oncology companies · Editorial + unicorn rating 4/10 rank vs industry peers · Fliar Intelligence Index 69/100 | $44M FY2025 | $14M | 18 mo ago | 380 380 → 243 (-36%) · sector median +28% | Rahul Batra Chairman & Managing Director | Top 10M | — | — |
| 2 | Hemogenomics Provider of blood screening technology for the early detection of diseases | $12M FY2025 | $219K | 214 mo ago | 98 98 → 125 (+28%) · sector median +28% | Sumit Bagaria CEO & MD | Top 10M | — | 1 launch |
| 3 | Datar Genetics Provider of liquid biopsy-based cancer diagnostic test | $12M FY2025 | $742K | 21 mo ago | 175 | Rajan Datar Founder | Top 5M | — | — |
| 4 | Panacea Developer of devices for radiotherapy 50Moat top 22%Market top 38%Talent top 38%Fin. health top 39% All 8 signals ▾Moattop 22% Markettop 38% Talenttop 38% Fin. healthtop 39% Fundingtop 42% Growthtop 48% Globalbottom 37% Techbottom 19% Moat: Top 6% by revenue among 34 tracked Oncology companies · Editorial + unicorn rating 5/10 Market: 336 employees (top 4% of Life Sciences) · Revenue ~$11.8M rank vs industry peers · Fliar Intelligence Index 50/100 | $12M FY2025 | $10M | 17 mo ago | 336 | Raghu Padmanabhan Co-Founder & CEO | Top 5M | — | — |
| 5 | ImmunoACT Developer of cell and gene therapies for cancer treatment | $8M FY2025 | $16M | 36 mo ago | 139 139 → 193 (+39%) · sector median +28% | Atharva Karulkar Co-Founder | Top 5M | — | 2 job openings |
| 6 | 1Cell.Ai Developer of AI-powered single-cell multi-omic analysis tools for precision oncology 69Growth top 20%Market top 43%Funding top 44%AI top 45% All 9 signals ▾Growthtop 20% Markettop 43% Fundingtop 44% AItop 45% Producttop 47% Techtop 48% Talentbottom 49% Fin. healthbottom 48% Globalbottom 45% Growth: Revenue +95% YoY · Web rank 10,000,000 → 5,000,000 YoY Market: Revenue ~$5.0M · Top 8% by revenue among 130 tracked Genomics peers rank vs industry peers · Fliar Intelligence Index 69/100 | $5M FY2025 | $16M | 18 mo ago | — | Mohan Uttarwar Co-Founder & CEO | Top 5M | — | — |
| 7 | Bugworks Research Developer of drugs for antibiotic-resistant bacterial infections and cancer | $3M FY2025 | $43M | 27 mo ago | 31 31 → 47 (+52%) · sector median +28% | Bala Subramanian Co-Founder & COO | Top 10M | — | — |
| 8 | Curadev Pharma Developer of small molecule immunotherapy drugs for cancer and inflammation | $2M FY2025 | $881K | 170 mo ago | 38 38 → 42 (+11%) · sector median +28% | Arjun Surya Founder | Top 50M | 87 patents Small‑molecule STING antagonists (urea derivatives) for immunomodulatory therapeutics | 4 job openings |
| 9 | BioGenomics Developer of recombinant DNA-based biosimilars, recombinant proteins, and enzymes | $1M FY2023 | $25M | 47 mo ago | 136 136 → 288 (+112%) · sector median +28% | Sanjay Sonar Co-Founder & Owner & President & CEO | Top 5M | 34 patents Recombinant protein expression systems and insulin/analog production technologies | — |
| 10 | Perfint Healthcare Developer of solutions for image-guided interventional procedures | $1M FY2025 | $41M | 109 mo ago | 31 | Gopalkrishna Kulkarni ex-Co-Founder | Top 10M | 28 patents Robotic and sensor‑guided needle positioning for image‑guided minimally invasive procedures | 4 job openings · 1 internship |
| 11 | OncoStem Developer of prognostic tests for the detection of cancer | $1M FY2025 | $9M | 105 mo ago | 19 | Manjiri Bakre Founder & CEO | Top 50M | — | — |
| 12 | Immuneel Developer of T-cell therapies for the treatment of cancer 40Moat top 31%Funding top 40%Growth top 46%Market top 49% All 9 signals ▾Moattop 31% Fundingtop 40% Growthtop 46% Markettop 49% Talentbottom 49% Fin. healthbottom 44% Globalbottom 39% Techbottom 31% Newsbottom 18% Moat: Top 21% by revenue among 34 tracked Oncology companies · Editorial + unicorn rating 7/10 Funding: Raised $39.3M across 4 rounds · 4 rounds over 7 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 40/100 | $1M FY2025 | $39M | 23 mo ago | 67 67 → 112 (+67%) · sector median +28% | Siddhartha Mukherjee Co-Founder | Top 5M | — | — |
| 13 | Issar Pharmaceuticals Developer of customied peptide-based therapeutic products | $1M FY2024 | $4M | 88 mo ago | 2 | Ram Isanaka Founder and Chairman | — | — | — |
| 14 | Sekkei Bio Developer of drugs and vaccines to treat multiple diseases | $893K FY2025 | $2M | 32 mo ago | — | Monalisa Chatterji Co-Founder | Top 10M | — | — |
| 15 | Epigeneres Provider of genomics based diagnostic tests for cancer | $877K FY2025 | $8M | 24 mo ago | 75 75 → 85 (+13%) · sector median +28% | Ashish Tripathi Founder & Chairman | Top 10M | — | 1 job opening |
| 16 | PredOmix Developer of cancer detection blood test | $826K FY2025 | $662K | 83 mo ago | 17 | Kanury Rao Co-Founder | Top 50M | — | — |
| 17 | Zumutor Developer of novel immunotherapy and monoclonal antibody therapeutics 22Innovation top 34%Product top 36%Funding top 42%Tech top 50% All 10 signals ▾Innovationtop 34% Producttop 36% Fundingtop 42% Techtop 50% Globalbottom 43% Moatbottom 40% Growthbottom 33% Marketbottom 29% Newsbottom 27% Fin. healthbottom 16% Innovation: 4 product lines Product: 4 distinct product lines · Company stage: Series A rank vs industry peers · Fliar Intelligence Index 22/100 | $547K FY2025 | $26M | 18 mo ago | 24 24 → 25 (+4%) · sector median +28% | — | Top 10M | — | — |
| 18 | Sapien Biosciences Provider of biobanking services to discover biomarkers and develop drugs and companion diagnostics | $428K FY2025 | — | 69 mo ago | 42 | Jugnu Jain Co-Founder & CEO | Top 50M | — | — |
| 19 | Theramyt Novobiologics Developer of treatment-altering biological drugs for multiple diseases | $406K FY2019 | $4M | 153 mo ago | 3 | — | — | 3 patents Manufacturing of exendin‑4 peptide therapeutics | — |
| 20 | Lamark Biotech Developer of thermostable biologics for treating diabetes and other diseases | $386K FY2025 | $41K | 16 mo ago | 8 | Vaibhav Bhatia Founder & CEO | — | 4 patents Controlled-release insulin formulations using hydrogel-based crystal seeding | — |
| 21 | Invictus Oncology Developer of chemotherapeutics conjugated with antibodies for the treatment of cancer | $339K FY2025 | $7M | 115 mo ago | 38 | Raghunath Mashelkar Co-Founder | — | 51 patents Lipid‑nanoparticle delivery of platinum chemotherapeutics and signaling‑inhibitor therapeutics | — |
| 22 | Eva Scalp Cooling Manufacturer of scalp cooling systems designed to minimize chemotherapy-induced hair loss | $312K FY2025 | $36K | 28 mo ago | — | Raghuveer Surupa Founder | Top 50M | — | — |
| 23 | Boltzmann AI powered drug discovery platform for cancer and autoimmune diseases | $214K FY2025 | $113K | 32 mo ago | — | Paritosh Prashar Co-Founder & CSO | Top 10M | — | 1 launch |
| 24 | TeraLumen Provider of terahertz-based non-destructive testing systems for industrial and biomedical applications | $213K FY2025 | $95K | 45 mo ago | 6 | Jyotirmayee Dash Co-Founder & CEO | Top 5M | 3 patents Patents concentrated in health & consumer products | — |
| 25 | InterpretOmics Provider of cloud-based analytics software for analyzing & interpreting genome data and diagnostics | $184K FY2016 | $2M | 113 mo ago | 52 | Amrith Prasad Co-Founder | — | — | — |
| 26 | Sāscan Developer of screening devices for the detection of cancer | $179K FY2025 | $339K | 61 mo ago | 16 | Subhash Narayanan Founder and CEO | Top 10M | — | 1 job opening · 1 award |
| 27 | APAC Biotech Developer of autologous monocyte-derived dendritic cell immunotherapy for cancer | $155K FY2025 | $991K | 182 mo ago | — | Arun Mehra CEO & MD | Top 50M | — | — |
| 28 | Mestastop Developer of cell-based functional assays for cancer metastasis focused drug discovery and predictive… 50Growth top 20%Patents top 35%Talent top 38%Tech top 43% All 11 signals ▾Growthtop 20% Patentstop 35% Talenttop 38% Techtop 43% Innovationtop 45% Moattop 47% Fundingtop 48% Fin. healthbottom 44% Globalbottom 40% Marketbottom 27% Newsbottom 22% Growth: Revenue +743% YoY · Fresh capital in last 24 mo Patents: 9 patents matched (strict assignee match) · 9 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 50/100 | $134K FY2025 | $1M | 18 mo ago | 12 | Debabani Chowdhury Co-Founder | Top 10M | 8 patents AI-driven cancer metastasis prediction and drug screening platforms | — |
| 29 | Tvaster Genkalp Developer of epigenetic-based liquid biopsy tests for cancer detection. | $109K FY2025 | $1M | 14 mo ago | 4 | Srikar Raman Co-Founder & CEO | Top 50M | 3 patents Epigenetic diagnostic kits detecting carcinomas via methylation markers without sequencing | — |
| 30 | Kyvor Genomics-based precision cancer diagnostics | $61K FY2024 | $160K | 106 mo ago | 11 | Abilesh Malli Gunasekar Founder & CEO | Top 50M | — | — |
| 31 | ExoCan Exosomes based oncodiagnostics and therapeutics healthcare technology solutions provider | $58K FY2025 | $73K | — | — | — | — | — | — |
| 32 | Aindra Provider of AI-powered cervical cancer detection system | $57K FY2025 | $62K | 60 mo ago | 20 | Adarsh Natarajan Founder & Co-Owner & CEO | Top 50M | — | — |
| 33 | Positive Bioscience Provider of DNA tests for cancer treatment & hereditary cancer screening | $43K FY2025 | $466K | 91 mo ago | 11 | Samarth Jain Co-Founder & CEO | — | — | — |
| 34 | East Ocyon Bio Developer of cell and gene therapies for the treatment of cancer | $38K FY2025 | $4M | 18 mo ago | — | Narinder Mehra Co-Founder & Director | Top 50M | — | — |
| 35 | NKure Theraputics Developer of NK cell therapies for the treatment of cancer | $34K FY2025 | $2M | 32 mo ago | 3 | Ashok Vohra Co-Founder | Top 50M | — | — |
| 36 | Erly Sign A platform providing test kits for detecting oral cancer | $16K FY2025 | $319K | 17 mo ago | 8 | Deovrat Begde Co-Founder | Top 50M | — | — |
| 37 | Ococur Developing nanoparticle based precision therapeutics for oncology | $13K FY2024 | $27K | 76 mo ago | — | Vijay Kanuru Founder & CEO | — | — | — |
| 38 | Kozhnosys Developer of breath analyzers to detect diseases | $12K FY2025 | $285K | 33 mo ago | 3 | Suman Kolarath Co-Founder | — | 9 patents Breath analysis devices detecting volatile organic compounds for medical diagnostics | 1 award |
| 39 | PNB Vesper Developer of therapies for treating pain, cancer, inflammation, and neurological disorders | $11K FY2024 | $919K | 158 mo ago | — | Padinjarethalakkal Balaram CEO & MD | — | 25 patents Hydroxy‑pyrrolone synthesis for immunomodulators and cholecystokinin receptor ligands | — |
| 40 | Exsure Developer of nano drug delivery platform for cancer treatment | $9K FY2025 | $358K | 8 mo ago | — | Swastika Paul Co-Founder | Top 50M | — | 1 internship |
| 41 | Pragmatech Healthcare Solutions Developer of a screening device for the detection of cervical cancer | $5K FY2025 | $131K | 27 mo ago | — | Palna Patel Co-Founder | Top 50M | — | — |
Top 12 Oncology companies in India
#1
Series A · Noida, Uttar Pradesh · founded 2021$1.9Mraised▾
Developer of cellular engineering methods and gene therapy based treatments. Research focuses on creating therapies for hematological malignancies, solid tumors, and blood disorders. Activities include the design of antigen targeting therapies and the application of gene editing techniques to modify hematopoietic stem cells. These approaches aim to address the underlying causes of inherited and metabolic conditions through cellular manipulation.
- May 2026Series A$2M
- Apr 2025Seed$885.6K
- Jan 2024Seed$1.8M
#2
Series A · Bengaluru, Karnataka · founded 2013 · 24 employees$26.2Mraised▾
Developer of novel immunotherapy and monoclonal antibody therapeutics. This company utilizes a proprietary human antibody platform to identify and develop first-in-class therapeutic antibodies. These antibodies target innate immunity and modulate the tumor microenvironment, focusing on targeted NK cell therapeutics within the immuno-oncology field. The company's approach centers on a platform for developing improved monoclonal antibody therapeutics. They maintain a commitment to scientific talent development within therapeutic research and development.
- Nov 2024Series A$730.4K
- Feb 2024Series A$720.3K
- Oct 2022Series A$241.3K
- Aug 2021Series A$6.2M
#3
Series A · Bengaluru, Karnataka · founded 2018 · 67 employees$39.3Mraised▾
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells. It has developed CAR-T cell therapy extracted from patient's blood cells to target cancerous cells. The product pipeline includes IMN-003A, IMN-001, and IMN-002 for leukemias and lymphomas.
- Jun 2024Series A$12M
- Apr 2022Series A$15M
- Sep 2020Series A$1.4M
- Nov 2019Series A$11M
#4
Series A · Mumbai, Maharashtra · founded 2021$16Mraised▾
Developer of AI-powered single-cell multi-omic analysis tools for precision oncology. The company provides platforms for clinicians, researchers, and biopharma partners, delivering real-time insights. Its technology supports personalized treatment decisions and continuous monitoring of disease progression. The company’s tools facilitate biomarker discovery, patient stratification, and targeted drug development.
- Nov 2024Series A$16M
#5
Public · Panchkula, Haryana · founded 2005 · 380 employees$13.9Mraised▾
Developer of therapeutics for oncology and dermatology. It offers nanoparticle –albumin–bound paclitaxel, docetaxel and gemcitabine in the form of tablets, capsules, oral liquids, and injectables. It also provide services including method development, qualification, validation, and transfer, stability protocol development, pre-formulation studies, and others.
- Nov 2024Post IPO$13.9M
#6
Series A · Kolar, Karnataka · founded 1999 · 336 employees$9.6Mraised▾
Developer of devices for radiotherapy. The product Bhabhatron MLC and Bhabhatron 3 are gamma therapy units, Imagin is an advanced radiotherapy simulator, Siddharth II has stereotactic Imaging, and Impact for immobilization and patient positioning. The company also has mammography units which include Lilac 2DC, Lilac 2DD, and Lilac.
#7
Series B · Bengaluru, Karnataka · founded 2014 · 31 employees$42.9Mraised▾
Developer of drugs for antibiotic-resistant bacterial infections and cancer. The Microbial Platform (BMP) is also capable of modeling the behavior and effect of biofilm formation. The lead compound, a Gyrase-topoisomerase inhibitor, is being developed as an intravenous and oral treatment for multi-drug resistant infections, with a low risk of developing resistance because it inhibits two essential targets in the replication machinery and has been designed to by-pass efflux resistance mechanism of the bacteria.
- Feb 2024Series B$6.8M
- Dec 2021Series B$18M
- Apr 2021Grant (prize money)—
- Apr 2020Series B$7.5M
#8
Seed · Gurugram, Haryana · founded 2022$4.2Mraised▾
Developer of cell and gene therapies for the treatment of cancer. The company uses synthetic biology and non-viral cell engineering technology to develop allogeneic, off-the-shelf chimeric antigen receptor (CAR)-NK cell therapies for treating cancers, including solid tumors.
- Dec 2024Seed$4.2M
#9
Seed · Bhubaneswar, Odisha · founded 2021$358.1Kraised▾
Developer of nano drug delivery platform for cancer treatment. The company is developing exosome-based chemotherapeutic drug-delivery platform to facilitate precise and guided delivery of anti-cancer drugs into tumor cells and relapse-causing cells without harming the healthy cells.
- Oct 2025Seed$11.3K
- Jan 2025Seed$346.9K
#10
Seed · Chennai, Tamil Nadu · founded 2021 · 4 employees$1.3Mraised▾
{}
- Apr 2025Seed$1.2M
- Sep 2023Seed$1.3M
- Grant (prize money)—
#11
Seed · Bengaluru, Karnataka · founded 2018 · 12 employees$1.3Mraised▾
Developer of cell-based functional assays for cancer metastasis focused drug discovery and predictive diagnostics. It offers platform which include Metaassay, Metvivo, and Metscan for metastasis with a combination of in vitro tests for scoring compounds as per their inhibitory potential of metastasis and then progressing the lead molecules in genetically engineered xenograft models.
- Nov 2024Grant (prize money)$315.1K
- May 2024Seed$131.7K
- Dec 2023Seed$156.4K
- Aug 2023Seed$685.2K
#12
Series B · Mumbai, Maharashtra · founded 2008 · 75 employees$7.8Mraised▾
Provider of genomics based diagnostic tests for cancer. It offers HrC Test a proprietary blood-based diagnostic capable of detecting all types of cancers, including solid tumors, hematological malignancies, and soft tissue sarcomas and B³ (Blood-Based Biopsy) test for genetic analysis that provides deep insights into cancers presence, progression, and treatment pathways. It also offer Nutrigenomic Products such as NovaGenere and nCurcu which feature plant-based phytoextracts, antioxidants that are targeted at cellular rejuvenation, anti‑inflammation, and healthy aging.
- Jun 2024Series B$2M
- Dec 2021Series B$6M
- Apr 2018Series A$1.8M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Oncology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.